Investor Ideas #Potcasts
551 #Cannabis News and #Stocks on the Move; (TSXV: $PKAN.V) (TSXV: $EMHV) (CSE:
$EASY.C) (CSE: $IKNK.U.C) (TSXV: $KHRN.V) (OTCQX: $KHRNF)
Delta, Kelowna, BC, April 13, 2021 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/041321-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/04131PKAN-EMH-EASY-IKNK-KHRN.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public company announcements.
PureK
Holdings Corp.
(TSX-V:
PKAN), along with its majority-owned CBD subsidiary
company, PureKana LLC, ("PureKana"), announcedt hat it
has entered into a brand partnership with leading cannabis and CBD retailer Chemesis International Inc. (CSE:
CSI)
(OTC:
CADMF), under which PureKana’s industry-leading CBD products
will become available at hundreds of proprietary Chemesis kiosks throughout the
United States.
As a result of this partnership,
PureKana’s industry-leading range of products - including its flavored pure
hemp-derived CBD oils, sleep aids, immunity boosts, vegan CBD-infused gummies,
soothing CBD-infused topical creams, and CBD capsules - will become a part of
the permanent product offering for Chemesis’ A.I.-powered VICKI Intelligent
Self-Checkout platform.
Chemesis’ VICKI kiosks can be
deployed in high traffic areas like shopping malls, workplaces, and transit
hubs and feature proprietary technologies to enhance the cannabis retail
experience, including age verification, loss prevention, product education, and
A.I.-powered virtual assistant technologies.
"Our partnership with Chemesis
accelerates our omni-channel distribution of the PureKana Brand. CBD education,
innovation, and availability are foundational to our mission to enable wellness
authentically every day for our loyal consumers," said Kathy Casey, CEO of
PureK Holdings Corp.
"PureKana is a highly regarded
brand by consumers and within the industry for their quality and well branded
products," said President of Chemesis, Josh Rosenberg. "This
partnership will allow Chemesis and PureKana to develop a cohesive strategy to
bring high-quality products to consumers through an alternate route to market.
Working with a strong brand such as PureKana, will give the VICKI platform
another edge over typical brick and mortar dispensaries."
Emerald
Health Therapeutics, Inc. (TSXV:
EMH)
(OTCQX:
EMHTF) has
launched its new product line, SYNC™ Tabs, an innovative,
naturally-flavoured ingestible offering consumers a controlled 10 mg THC dose
with predictable onset and offset. This product line expands its offering under
its SYNC™ Wellness brand and is the second of Emerald's Defined Dose™ products.
The first provincial purchase orders have been received and, beginning April
13th, the tablets will be available to consumers at licensed cannabis retailers
and online in BC, Manitoba, and Newfoundland, with Alberta to follow.
Emerald's Cannabis 2.0 and 3.0
strategy focuses on leveraging science-based innovation to serve targeted
consumer preferences. This differentiated new product line builds on Emerald's
commitment to offering consumers defined dosing and predictable actions that
let them control their cannabis consumption experience. SYNC™ Tabs are designed
in a familiar tablet form that enables convenient yet discreet cannabis use.
With 10 mg of THC, SYNC™ Tabs offer
consumers the measured stringency of Emerald's Defined Dose™ standard, dissolve
under the tongue in about three minutes, and provide desired effects within 20
to 30 minutes. Offset is equally controlled, occurring within approximately 90
minutes of taking the tablet. This new product line follows the introduction of
Emerald's Nano Fast-Acting Spray product. Sublingual tablets add to the SYNC™
brand's line-up of non-smoking forms of cannabis products, which also include
CBD and THC cannabis oils.
Designed to serve customers' use of
cannabis for daily wellness routines, SYNC™ Tabs are sugar-free, gluten-free,
vegan and come in two natural flavours, cherry and mint. Produced with
100-percent coconut-derived MCT oil, the products offer a sustainably-produced
cannabis wellness option. Each pack contains 10 x 10 mg doses, offering 100 mg
of THC in total.
"Our product development
efforts are centered on providing consumers with distinctive cannabis products
offering controlled, predictable actions – with greater precision of dosing and
the onset and offset of effects," said Riaz Bandali, President and CEO.
"We have a talented product development team that is passionate about
science and innovation. They are moving additional new product lines toward
launches planned for the next few months and quarters, which we expect to start
positively impacting our growth."
SpeakEasy Cannabis
Club Ltd. (CSE:
EASY), a holder of a federal licence to cultivate, process
and sell cannabis under the Cannabis Act. announced that it
has entered the final stage of amending its sales license to allow the sale of
its extracts and concentrates.
Founder,
Marc Geen, "Extractions and concentrates are a rapidly growing and an
important part of the cannabis market in Canada. We are eagerly anticipating our licence that
once granted, will allow us to participate in this exciting segment of the
market. With our large inventory of flower, perfect for creating extracts and
concentrates, we are eager to enter the consumer extract market that will
become an important part of our business for years to come. Because of our
low-cost of production, we will be entering the market with the ability to be
very competitive with anyone out there. These are very busy and exciting times
and I am thrilled we will soon be able to show what we can do in this segment
of the market."
Currently,
SpeakEasy is licenced to sell its dried flower to consumers. With the addition of its expected sales
amendment, the Company will be well positioned to enter the market with a
robust lineup of products ranging from simple artisan style concentrates to
more complex live resin vape carts. Formulations have been prepared and brands
are ready to launch upon receipt of the amendment. The ability to create a
large and diverse range of products and be able to enter each market with a low
price point is predicted to give SpeakEasy a significant advantage over
companies without an outdoor flower production area.
Keeping
production and processing in-house is a critical way to keep costs low.
SpeakEasy, in partnership with Frontier Labs, produces, processes and packages
its product without losing margin to other companies by contracting out or
taking on the cost of shipping between facilities. With SpeakEasy's goal of
competing directly with "black market" pricing, keeping costs as low
as possible is crucial to our success. Starting with our low-cost input
material, which is expected to be among the lowest in the industry, and
carrying on to finished product by using efficient, cost effective methods
completed in-house, SpeakEasy is able to pass those cost savings on to
consumers and be a strong competitor in the market.
Founder,
Marc Geen, states, "Having a price advantage, focusing on genuine
high-quality and branding that is rooted in the legacy BC market will give us
the opportunity to stand out from the crowd. We are a unique company for many
reasons, and I believe we will be able to make ourselves well known for all the
right reasons across the country."
Ikänik Farms, Inc. (CSE:
IKNK.U) announced that
Pideka SAS., a wholly-owned subsidiary of Ikänik Farms, has successfully
completed its cooperative agreement with SGS Colombia SAS to design, initiate,
develop, and implement a normative standard for the international certification
of medicinal cannabis. This certification works to establish a new baseline
standard for the quality and safety of pharmaceutical grade cannabis products
known as the "GPTCP", or "Good Production Transformation &
Commercialization Practices Cannabis Pharma".
"Completing
this collaborative certificate with SGS Colombia is a milestone achievement and
a reflection of the company's dedication to best-in-class quality for the
cannabis industry." said Brian Baca, CEO of Ikänik Farms.
The
GPTCP certificate ensures the company maintains international standards and
differentiates itself by adhering to a global benchmark standard of quality for
the production cannabis.
With
the collaborative development of the SGS certified seal of self-regulation and
sustainability, industry best practices are promoted and fosters a competitive
approach to quality, through best in class and standardized processes across
the industry, providing end consumers with product confidence.
The
GPTCP encompasses facets of the requirements under various standards such as
the BPA, BPM, INVIMA, ICA, ISO 9001, SG-SST, EUGMP at both the national
(Colombian) and international levels.
The
quality certification and delivery of high-caliber products is one of the
Company's key objectives, supported through operating certifications obtained
for its operations, including (GACP, GMP FARMA, ISO-9001, and EUGMP)
Khiron
Life Sciences Corp. (TSXV:
KHRN) (OTCQX:
KHRNF), a vertically integrated cannabis leader with core
operations in Latin America and Europe, announced that it
has received UK Continuing Professional Development ("CPD")
accreditation for Khiron Academy, the Company's global medical cannabis
education platform.
Additionally, following its
accreditation, the Company has entered into a strategic partnership with Cellen
Therapeutics, a leader in digital healthcare in the UK and fellow founding
member of Project Twenty21, to increase patient access through medical cannabis
education initially. Khiron Academy will be made available to prescribers in
the UK that have registered with Cellen's MedCanHub, an emerging education
portal. Cellen is market leader, widely recognized for also launching the UK's
first digital pain clinic, Leva.
Tejinder Virk, President of Khiron
Europe, commented, "Over the last year, Khiron has seen a direct
correlation between physician education and patient access. With Khiron
Academy's CPD accreditation and through our strategic partnership with Cellen
Therapeutics, we are positioned to reach a growing number of medical
professionals, and in turn, provide patients with greater access to medical
cannabis products."
Eric Bystrom, CEO of Cellen
commented, "We are pleased to be joining forces with Khiron on educating
prescribing specialists in the UK. Khiron is a clear global leader in medical
cannabis education. We share common values in improving patient lives by
educating doctors and optimizing the standard of medical care. Our aim is to
create a practical guide for responsibly prescribing patients with safe and
efficacious medical cannabis products."
In the UK, Khiron continues to
leverage educational materials developed by the Company to train medical
professionals in Latin America, along with clinical data from thousands of
Khiron patients. In addition to Cellen's MedCanHub (accessible to medical
professionals at https://medcanhub.cellenhealth.com/ ),
Khiron Academy is available to members of the Medical Cannabis Clinicians
Society (MCCS) and core to the training of prescribing specialists for Project
Twenty21, a 20,000-patient observational study backed Drug Science in UK.
To date, the Company has trained
nearly 1000 medical professionals in Latin America and the UK. Over the last
year, physicians trained by Khiron in Latin America have issued over 13,000
prescriptions, with a compound monthly growth rate of nearly 50%. Khiron
Academy will be a platform for sharing the Company's clinical expertise, in
conjunction with clinical data arising from Khiron's wholly-owned clinics in
LatAm.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com website
and that this podcast is not an endorsement to buy products or services or
securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can
trade these stocks and other ideas on our site
using our list
of top stock trading apps including Robinhood ,
Acorn, Stash and others.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google Play
Music and most audio platforms available.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About
Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and
equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment